Revista Latinoamericana de Patología Clínica y Medicina de Laboratorio

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board

>Journals >Revista Latinoamericana de Patología Clínica y Medicina de Laboratorio >Year 1999, Issue 3

Reyes RGL, Mansilla OA, García ERM, Poblete PTJ, Gutiérrez GJN, Navarro RJ, Jiménez VM
Antithrombin III in non insulin dependent diabetes mellitus of patients with myocardial infarction
Rev Latinoamer Patol Clin 1999; 46 (3)

Language: Español
References: 37
Page: 159-165
PDF: 195.01 Kb.

Full text


Objective: To determine whether a relationship exists between antithrombin III (ATIII) levels and miocardial infarct (MI) by coronary thrombosis in the non-insulin-dependent diabetic patient. Materials and methods: A descriptive study of 99 non-insulin-dependent patients was carried out. Plasmatic levels of ATIII were measured. Group I included patients with MI on whom coronary angiography had been previously performed. Group II was made up of 32 patients with non-insulin-dependent diabetes mellitus (NIDDM) without miocardial infarct. Results: Group I was composed of 42 males (63%) and 25 females (37%) patients. The age interval of the group studied ranged from 42-82 years. On determination of ATIII levels, 50 (75%) were found in reference numbers (88-131%) and 17 (25%) with diminution. Forty-five patients exhibited a coronary obstruction level greater or equal to 85%. In 34 (50.7%) patients, the ATIII value was found in reference values, and in 11 (16.4%) of the patients, diminution was found (40-83%). Among the 22 patients with an obstruction grade of less or equal to 84% 16 (24%) presented normal activity, and six patients (9%) showed diminution. Additionally, the MI evolution interval ranged from 6-60 hours, noting that from 36 hours, percent of ATIII activity was diminished (40-83%). In group II, the percent of ATIII activity was found in the reference values, with a range of 88-115%. Conclusions: ATIII activity is not altered during the first 24 hours of MI. Although this study was not designed to evaluate MI evolution, we observed a correlation between MI evolution and diminution in ATIII activity.

Key words: Antithrombin 111, myocardial infarction, coronary thrombosis.


  1. Hughes A, McVerry BA, Wilkinson L, Goldstone AH, Lewis D. Diabetes: a hypercoagulable state? Haemostatic variables in newly diagnosed type 2 diabetic patients. Acta haematol 1983; 69:254-259.

  2. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28:1039-1057.

  3. Jarrett RJ. Epidemiology and public health aspects of non-insulin-dependent diabetes mellitus. Epidemiol Rev 1989; 11:151-71.

  4. Lowe GDO, Tromberg P, MC Ardle BM, Lorimer AR, Forbes CD. Increased blood viscosity and fibrinolytic inhibitor in type II hiperlipoproteinaemia. Lancet 1982; 27:472-75.

  5. Davies MJ, Thomas AC. Thrombosis and acute coronary lesions in sudden cardiac ischemic death. N Engl J Med 1984; 310:1137-1140.

  6. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326:310-318.

  7. Fuster V, Badimon J, Badimon L, Chesebro J. The pathogenesis of coronary artery disease and the acute coronary syndromes, II. N Engl J Med 1993; 325:410-418.

  8. Fuster V, Stein B, Ambrose J, Badimon L, Badimon J, Chesebro J. Atherosclerotic plaque rupture and thrombosis: evolving concepts. Circulation 1990; 82: 1147-1159.

  9. Russell PT, Bovill EG. Thrombosis and cardiovascular risk in the elderyl. Arch Pathol Lab Med 1992; 116: 1307-1312.

  10. Boisclair MD, Lane DA, Wilde JT, Ireland H, Preston FE. A comparative evaluation of assay for markers of activated coagulation and/or fibrinolysis: thrombin-antithrombin complex, D-dimer and fibrinogen/fibrin fragment E antigen. Br J Haematol 1990; 74: 471-9.

  11. Juhan-Vague I, Aless MC and Vague P: Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med 1996; 28: 371-380.

  12. Assman G and Schulte H. Identification of individuals at hihgrisk for miocardial infarction. Atherosclerosis 1994; 110 (Suppl): s11-s21.

  13. Kannel W, D’Agostino, Belanger A. Fibrinogen, cigarrete smoking and risk of cardiovascular disease: Insights from the Framingham Study. American Heart Journal 1992; 113: 1006-12.

  14. Meade T, Brozovic M, Chakrabati R, Haines A, Imeson J et al. Haemostatic function and ischaemic heart disease; principal results of the northwick park heart study. Lancet 1986; 6533-37.

  15. Koening W, Sund M, Ernst E, Mraz W, Hombach et al. Association between rheology and components of lipoproteins in human blood. Results from MONICA project. Circulation 1992; 85: 2197-2204.

  16. Koening W, Ernst E. The possible role of hemorrheology in atherothrombogenesis. Atherosclerosis 1992; 94: 93-107.

  17. Dientenfass L. Blood rheology in pathogenesis of the coronary heart diseases. Am Heart J 1969; 77: 139-147.

  18. Dientenfass L. Viscosity of blood in normal subjects and in patients suffering from coronary occlusion and arterial thrombosis. Am Heart J 1966; 71: 588-600.

  19. Mead TW, North WRS, Chakrabarti R, Haines AP. Population-based distributions of haemostatic variables. Br Med Bull 1977; 33: 283-288.

  20. Charlotte W, Pratt and Church F. Antithrombina: structure and function. Sem in Hematol 1991; 8(1): 3-9.

  21. Martínez-Murillo C, Quintana GS. Manual de hemostasia y trombosis. Bases fisiopatológicas y clínicas de las enfermedades hemorrágicas y trombóticas. 1996; Ed. Prado. Mex.

  22. Schafer AI. The hypercoagulable states. Ann Intern Med 1985; 102: 814-828.

  23. Von Kaulla E, Von Kaulla K. Antithrombin and disease. Am J Clin Pathol 1967; 48(1): 69-80.

  24. Kenneth A, Bauer MD. Laboratory Markers of Coagulation Activation. Arch Pathol Lab Med 1993; 117: 71-77.

  25. Hedner U, Nilsson IM. Antithrombin III in a clinical material. Thromb Res 1973; 3: 631-641.

  26. IL TESTTM Antithrombin III Chromogenic Substrate Assay Cat. No. 97574-15.

  27. Compendios de ILADIBA. Infarto de miocardio: perspectivas actuales de la terapia trombolítica y antitrombótica. Cardiología 1990 II:13-15.

  28. Fuster V. Conceptos actuales sobre la patogénesis y el manejo de los síndromes isquémicos coronarios agudos. Circulation 1988; 77:1213-1220.

  29. Férez Santander SM, De la Peña Almaguer E. Daño miocárdico por reperfusión: su impacto en la clínica. Parte I. Arch Inst Cardiol Méx 1998; 68:431-437.

  30. Férez Santander SM, De la Peña Almaguer E. Daño miocárdico por reperfusión: su impacto en la clínica. Parte II. Arch Inst Cardiol Méx 1998; 69:371-376.

  31. Daviet L, McGregor JL. Vascular biology of CD36: Roles of this new adhesion molecule family in different disease states. Thromb Haemost 1997; 78: 65-9.

  32. Gachet C, Hechler B, Leon C, Vialn C, Leray C, Ohlmann P. Activation of ADP receptors and platelet function. Thromb Haemost 1997; 78:271-5.

  33. Giddings JC, Rails H, Davies D, Jennings G, Tanswell. Enhanced platelet sensitivity to adenosine diphosphate (ADP) in patients with cardiac valve disease. Thromb Haemost 1997; suppl 1:61.

  34. MacFarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier. Nature 1964; 202:498.

  35. Davie EW, and Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964; 145:1310.

  36. Kennet KW. Endothelial cells in hemostasis, thrombosis, and inflammation. Hospital Practice 1992;15:145-166.

  37. Hedner U, Nilsson IM. Antithrombin III in a clinical material. Thromb Res 1973; 3:631-641.

>Journals >Revista Latinoamericana de Patología Clínica y Medicina de Laboratorio >Year 1999, Issue 3

· Journal Index 
· Links 

Copyright 2019